Biotica Taps Former Abbott Exec as New President & CEO

ST. PETERSBURG, FL--(Marketwired - August 02, 2016) - Biotica Pharmaceuticals Inc. (Biotica), a biopharmaceutical company and subsidiary of FutureWorld Corp., which engages in discovering, developing, and commercializing cannabinoid-based medicines for Neuropathic pain, Cancer, Alzheimer's, Parkinson, Esophagitis, and Immune Enhancement, announces today that it has elected Dr. P.C. Sundar as its President & CEO effective July 19, 2016. Dr. Sundar, through his years of experience working for fortune 100 pharmaceutical companies will lead the Company in discovering, developing, and commercializing cannabinoid-based medicines for Neuropathic pain, Cancer, Alzheimer's, Parkinson and Esophagitis.

Dr. Sundar has over 30 year's executive leadership experience in the pharmaceutical industries. As the CEO of Biotica, he brings expertise in growing and scaling businesses, developing winning strategies, operations, marketing, sales and innovation for global businesses and broad brand portfolios. During his 30-year career at Abbott Labs, and Bayer, Sundar held positions of increasing responsibility with strong proven results. Before joining the Biotica team, Sundar most recently served as a Senior Vice President of a Fortune 50 company. He has brought several FDA-approved drugs to market. He also built several collaborative ventures for these companies. Sundar's experience in the pharma sector is helping Biotica to be a lead player in endocannabinoid drug discovery. Sundar earned his PhD degree from Vanderbilt University.

Biotica Pharma is positioning to be a world-class research and development facility in endocannabinoid drug development. Biotica plans to set-up a state-of-the-art research and development lab to enhance the BPRx platform and rapidly expand its research capabilities. Biotica's research includes specific programs for eosinophilic esophagitis, Alzheimer's disease, frontotemporal dementia, Parkinson's disease and severe, chronic pain. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our therapies will use a BPRxTM platform to optimize the synergistic combination of photo and endocannabinoids to modulate disease pathology and progression. By significantly decreasing the production of relevant signaling and causative molecules at targeted sites within various tissue systems, the goal is to address the underlying biology of the disease and make a meaningful difference for patients. Our talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.

About Biotica Pharmaceuticals Inc.
Biotica Pharmaceuticals, a Delaware company, is an early-stage biotech founded by a group of pioneers in cannabis technology landscape. Biotica, a biopharmaceutical company, together with its subsidiaries, will engage in discovering, developing, and commercializing cannabinoid-based medicines. It will operate through three segments: 1) Commercial, 2) Drug delivery systems and methods such as hydrophobic, 3) Cannabinoids Research and Development for Neuropathic pain, Cancer, Alzheimer's, Parkinson, Esophagitis, and Immune Enhancement. Currently Biotica has one location in Florida and soon plans to add a second facility housing the lab in the State of Florida.

To request further information about Biotica Pharmaceuticals, please email us at info@bioticapharma.com, log onto our website at http://www.bioticapharma.com or visit us at our Facebook page facebook.com/bioticapharma or on Twitter @bioticapharma.

About FutureWorld Corp.
FutureWorld (OTC PINK: FWDG), a Delaware corporation, is a leading provider of advanced technologies and solutions to the global cannabis industry. FutureWorld, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of cannabis related products and services, such as industrial Hemp. FutureWorld, through its subsidiaries, provides personal and professional THC and HTD test kits, pharmaceutical grade HTD oil solutions, SafeVape vaporizers, smart sensor technology, communication network, surveillance security, data analysis for smart cultivation and consultation for the industrial hemp and legal medicinal cannabis. Our wireless agricultural smart sensor networks offer precision to the agriculture, irrigation systems, and greenhouses for the global cannabis and hemp industry. FutureWorld and its subsidiaries do not grow, distribute or sell marijuana. As the only Cannabis Technology Accelerator, FutureWorld will incubate and fund leading technologies, products, and services for Cannabis industry (Industrial Hemp) for foreseeable future; bringing value to its core and its shareholders.

Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.